Setting The Pace In The Race To Treat NASHPosted by Rosana Kapeller
Pivotal late-stage study of GENFIT's NASH candidate to commence this quarter By: Douglas W. House,
Logribel Biostocks
Long only, biotech, micro-cap, deep value
Phase 3 NASH Trials: Genfit's Drug Will Beat Intercept's OCA To Market
Intercept: What We Learn From OCA's Failure In Japan Phase 2 NASH Trial
NASH IS THE 21ST CENTURY’S LOOMING PUBLIC HEALTH THREAT
BY KIRA PEIKOFF ON 1/30/16 AT 2:50 PM
EASL NEWS on twitter during the Liver congress :
Actions de l'utilisateur
@EASLNews Twitter Ambassador | Former Executive Director @_MdMUSA@AIDSHealthcare & VP of Impact Initiatives @GBCHealth | #HCV …
Edny Inui @BMTEdny 
il y a 23 heures
Metabolic wrapup highlights target-based drugs in development for NAFLD/NASH #ILC2016 $ICPT $GILD $TBRA
Elafibranor shows high histological & metabolic efficacy in NASH eligible for pharmacotherapy #ILC2016
Gilead press release from #ILC2016 #EASL includes progress on Nimbus' ACC inhibitor NDI-010976 for NASH et al. http://www.gilead.com/news/press-releases/2016/4/gilead-presents-new-data-highlighting-progress-in-liver-fibrosis …
Gilead Sciences @GileadSciences 
Gilead announces new data evaluating investigational therapies for treatment of #NASH, #PSC http://bit.ly/1Yzfjw3 #ILC2016
Karin: How do ROS loose the ability to induce cell death and allow for liver #cancer development in #NASH? #ILC2016 @ILCpress @EASLnews
True about ... ont Retweeté
Okim59 a retweeté EASL Education
Genfit.. Non-invasive method for #NASH diagnosis #ILC2016 by Dr. Arun Sanyal https://twitter.com/easledu/status/721231556791169025 … http://www.genfit.fr/wp-content/uploads/2016/03/2016.03.30-CP-GENFIT-EASL.pdf …
@EASLedu
Non-invasive method for #NASH diagnosis #ILC2016 by Dr. Sanyal on #EASL Community Portal http://buff.ly/1r1A1dB
Seb. @seb_i1 
Barcelona, Spain
Did u see the @GENFIT_pharma booth $GNFT at the #ILC2016 in Barcelona #firabcn #Liverdisease #NASH #NAFLD @easlnews
Dr. Alonso: Specific serum metabolic patterns reflecting each NASH subtype , type 3 mainly polyunsaturated fatty acids #ILC2016
Strong efficacy of Elafibranor in severe NASH associated w/ strong reduction of cardiometablic risk, ePoster FRI-339 #liverdisease #ILC2016
Dr. C. Alonso: Why subtypes of #NASH: Identification of metabolic signatures could help understand #ILC2016
GS-9674, FXR agonist, reduces steatohepatitis in NASH mouse model, currently in PI $GILD #ILC2016
Nimbus Phase-1 SAD data for NDI-010976 (ACC inhibitor for NASH) presented at #ILC2016 #EASL for first time. http://nimbustx.com/sites/default/files/uploads/westlin_easl_2016_ph1sad_final.pdf …
#ILC2016 how do you stage NAFLD / NASH? Most use Fibroscan
Miss NASH? Well, Answering Unmet PBC Need @EASLnews @EASLedu #ILC2016 today 6:30 http://ow.ly/ZFVEz #pbcspain
Genfit #ILC2016 .poster Friday #NASH #ELAFIBRANOR #Sven Francque #Zouher Majd
Gilead Sciences @GileadSciences
Gilead is presenting results from studies of investigational compounds for the treatment of NASH at #ILC2016
#NimbusTx presents our NASH clinical data at #ILC2016 (Ph1a poster Fri, Ph1b data oral presentation Saturday)
#ILC2016 NASH ePoster session starts now. FXR agonists up first.
NASH symposium, Pr. Ratziu: Case study: a woman with insidious progression of NASH #ILC2016
NASH symposium, NASH: Optimizing therapy for progressive disease – Organized by GENFIT: #ILC2016
Registration for Understanding the Role of Evolving Targets in NASH @EASLnews @EASLedu #ILC2016 is now open! North Entrance, Hall 8, Rm B3
Check out @InterceptPharma 's presentation on #NASH and @Norgine's on hepatic encephalopathy this evening #ILC2016 http://ow.ly/10wDHO
GENFIT ~ #ILC2016 NASH Symposium Vlad D.Ratziu : What New Therapies Are on the Horizon; Efficacy and Safety Profiles
Dr. Shalapour: Serum IgA correlates with fibrosis in human and mouse NASH/NAFLD #ILC2016
Dr. Harrisson: summarizing slide on Pathogenesis of NAFLD/NASH #ILC2016
Non-invasive method for #NASH diagnosis #ILC2016 by Dr. Sanyal on #EASL Community Portal http://buff.ly/23ryqPe
Thank you @EASLnews @EASLedu for this great #ILC2016. The Swiss Liver Center looks forward to joining #ilc2017 @adegottardi @dufour_jf
Henry E. Chang @HenryEChang
il y a 21 heures
In great company; top influencers of #ILC2016 @JMPawlotsky @gregpavillon @seb_i1 @EASLnews @EASLedu @ILCpress
Many Ways, One Aim: Beating Liver Disease. #ILC2016 #HomeofHepatology @EASLnews @EASLedu @gregpavillon @EASL_Sec_Gen
Good morning #ILC2016 attendees! Wishing you all a fruitful day 4! @EASLnews @ILCpress @gregpavillon
Sonal Kumar, MD MPH @SonalKumarMD 
Great algorithm for non-invasive NAFLD risk stratification #ILC2016 #nafld @EASLnews
History in the making! Elimination statement signed and shared with WHO @EASLnews @GHirnschall #ILC2016
What a brilliant idea to make the long hallway an art exhibition! Well done @ILCpress @EASLnews #ILC2016 #liver art
Journal Hepatology et 1 autre ont Retweeté
Come and pick EASL @JHepatology last issues and #CPG's available @EASLnews Booth Hall 8.0 #ILC2016 @Fira_Barcelona
Excellent review on dysbiosis and liver disease by Svegliati-Baroni at #ILC2016 Basic Science Seminar! @EASLnews @UEGMedia @my_ueg
Pierre Gholam @pgholam 
Barcelona, Spain
@EASLnews the #ILC2016 version of dejeuner sur l'herbe
---------------------------------------------
NEW
A very good NASH drugs pipe overview in chinese is here
A very good PBC and NASH trials presentation is here
The full publication of GOLDEN results in Gastroenterology
